Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Hutchison MediPharma"
Count: 90
Selected: 0
NCT IDTitle
NCT03778229Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
NCT03251378A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer
NCT04577963A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
NCT04322539A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer
NCT04755088Surufatinib Renal Impairment Study
NCT05467943Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma
NCT03128164A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed
NCT05535933HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
NCT03223376A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
NCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma
NCT04755075Surufatinib Hepatic Impairment Study
NCT02549937A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
NCT05509699Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
NCT05429008A Phase I Clinical Study of HMPL-A83 in Patients With Advanced Malignant Neoplasm
NCT05318820A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers
NCT05277454Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
NCT05173142HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors
NCT04762602A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
NCT05077384Open-label Study of Surufatinib in Japanese Patients
NCT05190068HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05015608Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
NCT05009836Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
NCT02897479A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer
NCT05015621A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
NCT04923945Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
NCT04923932Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
NCT04169672Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
NCT04908046A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
NCT05029635Phase III Study on HMPL-523 for Treatment of ITP
NCT02589821Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
NCT04645940Fruquintinib Food Effect and Proton Pump Inhibitor Study
NCT04557397Fruquintinib CYP3A Inhibitor and Inducer Study
NCT04510649Surufatinib DDI With a PPI and a CYP3A Inducer
NCT04849351Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
NCT04372394A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy Subjects
NCT02588170Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
NCT04372407A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy Subjects
NCT03951623The Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Immune Thrombocytopenia Patients
NCT03903705Fruquintinib in Combination With Sintilimab in Patients With Advanced Solid Tumor
NCT02503033A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
NCT00659802Phase II Study of HMPL-004 in Patients With Ulcerative Colitis
NCT02133157Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
NCT04353375Phase II Study of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma With FGFR2 Fusion
NCT04290325HMPL-453 in Advanced Malignant Mesothelioma
NCT04272957A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms
NCT03231501HMPL-813 in Treating Patients With Glioblastoma
NCT02196688Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
NCT04005066Study of Elunate® (Fruquintinib) in Chinese Patients With Advanced CRC
NCT02320409A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)
NCT02374645A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC